High serum levels of leucine-rich α-2 glycoprotein 1 (LRG-1) are associated with poor survival in patients with early breast cancer
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.High serum levels of Leucine-rich α-2 glycoprotein 1 (LRG-1) correlate with poorer survival in early breast cancer (BC) patients. This finding suggests LRG-1 is a potential independent prognostic biomarker for BC.
Area Of Science
- Biochemistry
- Oncology
- Biomarker Discovery
Background
- Leucine-rich α-2 glycoprotein 1 (LRG-1) is a secreted glycoprotein implicated in various pathologies, including cancer.
- Elevated intratumoral LRG-1 expression in early breast cancer (BC) is linked to reduced patient survival.
Purpose Of The Study
- To assess serum LRG-1 levels in early BC patients.
- To investigate the correlation between serum LRG-1 levels, disseminated tumor cells (DTCs), and survival outcomes.
Main Methods
- Serum LRG-1 levels were quantified in 509 BC patients using ELISA.
- Disseminated tumor cells (DTCs) were detected via immunocytochemistry.
- Kaplan-Meier survival analysis and multivariate Cox regression were employed to evaluate prognostic relevance.
Main Results
- Higher serum LRG-1 levels were observed in older and postmenopausal patients.
- Patients with no DTCs exhibited significantly elevated LRG-1 levels.
- High serum LRG-1 levels were associated with significantly lower overall and BC-specific survival (p=0.0003).
- LRG-1 was identified as an independent prognostic marker for BC-specific survival (p=0.001).
Conclusions
- Serum LRG-1 shows potential as an independent prognostic biomarker for early breast cancer.
- Further research may elucidate LRG-1's role in BC progression and patient outcomes.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...